Tags

Type your tag names separated by a space and hit enter

Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
Int J Hematol. 2019 Apr; 109(4):377-381.IJ

Abstract

We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-negative status. MRD-negative status is considered a treatment milestone in multiple myeloma (MM). We used 45 bone marrow samples from patients with MM, including 11 cases treated with anti-CD38 monoclonal antibody. The SRL-Flow sample preparation protocol was identical to that of EuroFlow-NGF. The antibody panel for SRL-Flow was as follows: CD138V450/CD27V500/CD38ME (multiepitope)FITC/CD56PE/CD45PerCP-Cy5.5/CD19PE-Cy7/cytoplasmic (Cy) immunoglobulin (Ig) κAPC/CyIgλAPC-H7. To identify abnormal plasma cells (aPCs) of patients with MM who received anti-CD38 monoclonal antibody, we used a panel of anti-CD45 and anti-CD138 antibodies (Abs) rather than a panel of anti-CD45 and anti-CD38 Abs. We comparatively analyzed the total nucleated cell numbers, total PC levels, and MRD levels between the SRL-Flow and EuroFlow-NGF. High correlations (r > 0.9) in total PC and MRD levels were noted among SRL-Flow, original EuroFlow-NGF (2 tubes), and EuroFlow-NGF (tube 2 only), suggesting that SRL-Flow is an inexpensive (< $200 USD/sample as of January of 2019) alternative to EuroFlow-NGF (< $350 USD/sample) for assessing MRD in MM.

Authors+Show Affiliations

Department of Hematology and Respirology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan. takamaz@staff.kanazawa-u.ac.jp.Department of Hematology and Respirology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.Department of Hematology and Respirology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.Cellular Immunology Analysis Section, Genetic and Chromosome Analysis Department, SRL, Inc, Tokyo, Japan.Cellular Immunology Analysis Section, Genetic and Chromosome Analysis Department, SRL, Inc, Tokyo, Japan.Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan.Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan.Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan.Department of Hematology and Respirology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.Department of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

30778767

Citation

Takamatsu, Hiroyuki, et al. "Comparison of Minimal Residual Disease Detection in Multiple Myeloma By SRL 8-color Single-tube and EuroFlow 8-color 2-tube Multiparameter Flow Cytometry." International Journal of Hematology, vol. 109, no. 4, 2019, pp. 377-381.
Takamatsu H, Yoroidaka T, Fujisawa M, et al. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol. 2019;109(4):377-381.
Takamatsu, H., Yoroidaka, T., Fujisawa, M., Kobori, K., Hanawa, M., Yamashita, T., Murata, R., Ueda, M., Nakao, S., & Matsue, K. (2019). Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. International Journal of Hematology, 109(4), 377-381. https://doi.org/10.1007/s12185-019-02615-z
Takamatsu H, et al. Comparison of Minimal Residual Disease Detection in Multiple Myeloma By SRL 8-color Single-tube and EuroFlow 8-color 2-tube Multiparameter Flow Cytometry. Int J Hematol. 2019;109(4):377-381. PubMed PMID: 30778767.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. AU - Takamatsu,Hiroyuki, AU - Yoroidaka,Takeshi, AU - Fujisawa,Momoko, AU - Kobori,Kazuya, AU - Hanawa,Masako, AU - Yamashita,Takeshi, AU - Murata,Ryoichi, AU - Ueda,Mikio, AU - Nakao,Shinji, AU - Matsue,Kosei, Y1 - 2019/02/18/ PY - 2019/01/10/received PY - 2019/02/08/accepted PY - 2019/02/08/revised PY - 2019/2/20/pubmed PY - 2019/4/18/medline PY - 2019/2/20/entrez KW - EuroFlow KW - Minimal residual disease KW - Multiparameter flow cytometry KW - Myeloma SP - 377 EP - 381 JF - International journal of hematology JO - Int. J. Hematol. VL - 109 IS - 4 N2 - We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-negative status. MRD-negative status is considered a treatment milestone in multiple myeloma (MM). We used 45 bone marrow samples from patients with MM, including 11 cases treated with anti-CD38 monoclonal antibody. The SRL-Flow sample preparation protocol was identical to that of EuroFlow-NGF. The antibody panel for SRL-Flow was as follows: CD138V450/CD27V500/CD38ME (multiepitope)FITC/CD56PE/CD45PerCP-Cy5.5/CD19PE-Cy7/cytoplasmic (Cy) immunoglobulin (Ig) κAPC/CyIgλAPC-H7. To identify abnormal plasma cells (aPCs) of patients with MM who received anti-CD38 monoclonal antibody, we used a panel of anti-CD45 and anti-CD138 antibodies (Abs) rather than a panel of anti-CD45 and anti-CD38 Abs. We comparatively analyzed the total nucleated cell numbers, total PC levels, and MRD levels between the SRL-Flow and EuroFlow-NGF. High correlations (r > 0.9) in total PC and MRD levels were noted among SRL-Flow, original EuroFlow-NGF (2 tubes), and EuroFlow-NGF (tube 2 only), suggesting that SRL-Flow is an inexpensive (< $200 USD/sample as of January of 2019) alternative to EuroFlow-NGF (< $350 USD/sample) for assessing MRD in MM. SN - 1865-3774 UR - https://www.unboundmedicine.com/medline/citation/30778767/Comparison_of_minimal_residual_disease_detection_in_multiple_myeloma_by_SRL_8_color_single_tube_and_EuroFlow_8_color_2_tube_multiparameter_flow_cytometry_ L2 - https://dx.doi.org/10.1007/s12185-019-02615-z DB - PRIME DP - Unbound Medicine ER -